Randomized Trialhigh evidence
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
The New England journal of medicine·July 9, 2026·PMID 42418774
Why it mattersAcquired hypothalamic obesity is a severe, treatment-resistant condition with limited options. This trial provides high-level evidence that setmelanotide can produce clinically meaningful weight loss and hunger reduction, addressing a critical unmet need in this population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled